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The antifungal activity of magnolol and honokiol, two naturally occurring hydroxylated biphe-
nyls, and of their synthetic derivatives was evaluated on a collection of representative iso-
lates of Fusarium oxysporum, F. solani and F. verticillioides of clinical and ecological
concern. The tested compounds were proposed as a ‘natural’ alternative to conventional
fungicides, even though a larger range of concentrations (5–400 μg/ml) was applied. The
activity of magnolol and honokiol was compared with that of terbinafine (0.1–10 μg/ml), and
fluconazole (1–50 μg/ml), two fungicides widely used in treating fungal infections on
humans. Magnolol showed similar fungicidal activity compared to fluconazole, whereas hon-
okiol was more effective in inhibiting mycelium growth compared to this fungicide on all
tested clinical Fusarium spp. isolates. Compared to terbinafine, honokiol showed similar
antifungal activity when tested on clinical F. solani isolates, whereas magnolol was less
effective at all selected concentrations (5–400 μg/ml). The different position of the phenol-
OH group, as well as its protection, explain different in vitro activities between magnolol,
honokiol, and their derivatives. Furthermore, magnolol showed mycelium dry weight reduc-
tion at a concentration of 0.5 mM when tested on a set of agricultural isolates of Fusaria,
leading to complete inhibition of some of them. Magnolol and honokiol are proposed as effi-
cient and safe candidates for treating clinically relevant Fusaria.
Introduction
Natural occurring polyphenols are a great source of biologically active compounds beneficial
to human and animal health [1]. Magnolol (1, 5,5’-diallyl-2,2’-dihydroxybiphenyl) and hono-
kiol (2, 5,5’-diallyl-2,4’-dihydroxybiphenyl) are two hydroxylated biphenyl-type neolignans
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and represent the main components of the bark of Magnolia officinalis, M. obovata, M. grandi-
flora and M. dealbata [2] These compounds have long been important substances in tradi-
tional Chinese and Ayurvedic medicine due to their wide biological activities [3]. Magnolol 1
and honokiol 2 are chemically stable and commercially available in large amounts at a reason-
able price. In the bark of M. officinalis, magnolol 1 and honokiol 2 were identified in ratios of
approximately 4:1; honokiol 2 ranges from 17 to 19 mg/g of extract, whereas magnolol 1 is
present in the roots at a concentration of 87–96 mg/g. Although the main source of magnolol
1 and honokiol 2 are species ofMagnolia growing in China, Japan and South Korea, both com-
pounds are also found in other species of this genus present in Mexico. In Asia, these com-
pounds are used in modern clinical practice, while in the United States and Europe are
considered cosmetic additives [3].
The unique pharmacophore structure of magnolol 1 and honokiol 2, formed by two
hydroxylated aromatic rings bridged by a single C-C bond representative of the hydroxylated
biphenyl structure, has a crucial role in their biological activity [4]. This structural feature
allows the activation of a large number of interactions with the surface of proteins [5].
The spectrum of inflammatory diseases to which they provide relief is broad, including
allergic rhinitis, influenza and diarrhoea, but also myocardial infarction and anxiety episodes
[3, 6]. The biological activity of magnolol 1 and honokiol 2 is likely to depend on the hydroxyl
group located at the biphenyl moiety and the allyl chain in para (magnolol 1 and honokiol 2)
and in ortho (honokiol 2) position to the phenol-OH group, which adds further features to
these molecules, such as anti-oxidative, anti-proliferative, anti-fungal, anti-tumoral, anti-HIV
and neuroprotective activities [3, 7–10]. This wide array of positive properties makes the two
molecules potential candidates in the search for new drugs effective at treating various inflam-
matory diseases, such as osteoarthritis or acne, but also for prophylaxis of biofilm-forming
streptococci causing caries [11].
In hospitals, multi-resistant bacterial and poorly treatable fungal infections have become a
serious problem in recent years [12, 13]. Invasive filamentous fungal infections have a growing
incidence in immune-compromised subjects such as AIDS patients, recipients of kidney trans-
plants or people suffering from haematological diseases [14]. Among them, Fusarium spp. are
common human pathogenic fungi implicated in invasive mycoses and infections. Fusariosis is,
after aspergillosis, the second most common mould infection in humans [15, 16]. In healthy
humans, Fusarium spp., particularly F. verticillioides, F. solani and F. oxysporum, are frequently
reported as the cause of dermatological affections such as onychomycoses and paronychia, but
they may also induce keratitis episodes, mainly as a consequence of contaminated lens solu-
tions [17]. F. solani and F. oxysporum represent the major opportunistic human pathogenic fil-
amentous fungi, being responsible for approximately two-thirds of the reported fusarioses. In
immune-compromised patients, Fusarium infections lead to disseminated fusarioses, which
are frequently fatal. In addition to an often-late diagnosis of Fusarium spp. infection, currently
administrated antifungal drugs are poorly effective due to the high degree of resistance shown
by representatives of this genus [15].
Fusarium spp. are present in several ecosystems including agricultural soil, with relevant
impact on cereal crops [18, 19]. Among other species, F. graminearum and F. culmorum are
the main pathogens causing Fusarium head blight (FHB) and foot and root rot (FRR) on
wheat and other small grains, where they induce yield losses, poor grain quality and contami-
nation with type-B trichothecene mycotoxins [20]. Fungicides bearing an azole unit are widely
used for plant and human protection against Fusarium spp., as they are generally inexpensive,
have a broad-spectrum of action and long stability. However, in recent years, large-scale
deployment of azole fungicides in agriculture has been considered as a potential cause of the
increasing resistance phenomena found also in human pathogenic fungi [21]. Despite different
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plant extracts are effective against human fusarioses [22], the scarce availability of natural
sources from which large amounts of them can be obtained at stable concentrations hamper
their application.
In our previous studies devoted to the search of effective sustainable fungicides in agricul-
ture, we observed antifungal activity of magnolol 1 against F. graminearum and F. culmorum,
both in vitro [23] and in silico [24]. Magnolol 1 manifested the highest anti-fungal activity
among a wide range of natural occurring phenols, with fungal growth inhibition at concentra-
tions as low as 0.125 mM. Furthermore, magnolol 1 and honokiol 2 are generally recognised
as harmless for humans and animals [25]. Cytotoxicity (IC50) against normal human lympho-
cytes was set at 38.6 μM for magnolol 1 and 16.1 μM for honokiol 2 [26]. Both compounds are
metabolized by extrahepatic and hepatic pathways, producing mainly glucuronic derivatives.
Moreover, magnolol 1 is not phytotoxic at concentrations up to 1.5 mM [23]. Considering that
many antifungal drugs exert toxic effects on human cells, these characteristics make magnolol
1 and honokiol 2 excellent candidates as sustainable and commercially available fungicides
against human and animal pathogens. However, the poor aqueous solubility of magnolol 1
and honokiol 2, common in natural polyphenols, has hampered their broad clinical applica-
tion. In order to overcome this issue, encapsulation of honokiol has been assessed [27] and
synthetic derivatives were prepared [28]. Nevertheless, derivatives and improved formulations
of these compounds are often limited by toxicity and drug interaction, hence preventing their
use in medical practice. The pro-drug approach [29] represents a versatile strategy to improve
the bioactivity of such molecules by transformation of the hydroxyl groups of magnolol 1 and
honokiol 2 in an ester group with a mono- and diacetyl functional group or in an acetal group
with a glucose unit, respectively. These ester or acetal groups would undergo in vivo biotrans-
formation trough chemical or enzymatic cleavage, thus favouring the delivery of the active
compound with a higher yield.
Aims of the present work were: 1) to evaluate the inhibitory activity of magnolol 1 and hon-
okiol 2 over a collection of Fusarium spp. isolates of clinical and phytopathogenic interest, and
2) to develop derivatives of magnolol 1 and honokiol 2 with improved water solubility and
equal inhibitory activity compared to the parental compounds. In a preliminary experiment,
the spectrum of activity of magnolol 1 was tested against representative isolates of Fusarium
species of relevant human concern or of phytopathogenic interest. Subsequently, magnolol 1,
honokiol 2, and their derivatives (compounds 3–8, Fig 1) were tested for their anti-fungal
activity and specificity towards human and nosocomial isolates. The activity of these com-
pounds was compared with that of terbinafine and fluconazole, two common fungicides. To
our knowledge, this is the first time that magnolol 1 and honokiol 2 are assayed over a collec-
tion of Fusarium spp. relevant to both plant and human health.
Material and methods
Strains and culture
In a preliminary screening, thirty-two Fusarium spp. isolates from the collection of the Univer-
sity of Sassari (PVS-Fu) sampled from soil (10 isolates), diseased plants (9 isolates), and from
human specimen (13 isolates) and water tap (1 isolate) in different Italian hospitals were tested
against magnolol 1 (Table 1).
Subsequently, a selection of F. oxysporum, F. solani and F. verticillioides isolates from the
PVS-Fu collection, collected from human samples, water tap, and basin sink in different Italian
hospitals and identified morphologically and molecularly by analysis of the elongation factor
gene sequence (TEF-1α) was tested (Table 2).
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Chemical materials
Magnolol 1 and honokiol 2 were purchased from Chemos GmbH, Germany. Magnolol mono
acetate 3, magnolol diacetate 4, honokiol 2-mono acetate 5, honokiol 4’-mono acetate 6 and
honokiol diacetate 7 (Fig 1) were prepared as previously described [8]. All compounds were
synthesized with the same purity obtained before and judged by 1H-NMR spectral determina-
tion (in Supporting Information S1 Text). Magnolol mono glucopyranoside 8, β-anomer, was
prepared under chemical and sustainable conditions starting from magnolol-2-O-(2’,3’,4’,6’-
tetra acetyl)-β-D-glucopyranoside. Structure of 8 was confirmed by comparison with spectro-
scopic data present in literature of an identical β-anomer achieved under enzymatic conditions
(S1 Text in Supporting information).
Lipophilicity estimation
Lipophilicity was estimated using the logarithm of the partition coefficient for n-octanol/water
(log P), implemented in the ChemBioDraw Ultra 13.0 software.
Evaluation of antifungal activity in Vogel’s medium
In a preliminary assay, the antifungal activity of magnolol 1 at 0.5 mM was evaluated according
to Pani et al. [23] on thirty-two isolates of Fusarium spp. (Table 1). Vogel’s medium was
amended with 0.5 mM of magnolol 1 and sonicated for one hour at room temperature. Three
replicates of 104 conidia in 8 ml of Vogel’s/magnolol 1 medium for each strain were cultured
at 25˚C in the dark without shaking. After 14 days, mycelia were recovered, filtered and dried
at 85˚C for 48 h. Inhibition was expressed as dry weight percentage of the untreated test.
Evaluation of antifungal activity in potato dextrose agar (PDA)
In a second test, the antifungal activity of magnolol 1, honokiol 2 and their derivatives 3–8
(Fig 1) was assessed by comparison with terbinafine and fluconazole, two common fungicides
of clinical use, on a selection of F. oxysporum, F. solani and F. verticillioides isolates collected
Fig 1. Chemical structures of magnolol 1, honokiol 2 and derivatives 3–8.
https://doi.org/10.1371/journal.pone.0221249.g001
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from different Italian hospitals (Table 2). Concentration of compounds 1–4 and 8 ranged
from 5 to 400 μg/ml, while concentrations between 5–100 μg/ml were used for compounds 5–
7. The concentrations of terbinafine and fluconazole ranged from 0.1–10 μg/ml and 1–50 μg/
ml, respectively. Antifungal activity was measured after three days of growth on potato dex-
trose agar (PDA) medium at 25˚C in the dark in the presence of the different concentrations
(μg/ml) of each compound and expressed as the colony diameter in percentage relative to con-
trol. Concentrations of conventional fungicides were selected according to clinical dosage and
standard experimental procedures [30]. PDA was amended with each inhibitor suspension
previously sonicated for an hour at room temperature. Conidial suspensions of each strain
Table 1. List of the set of 32 Fusarium spp. isolates obtained from soil (10 isolates), diseased plants or grain (9 isolates), water tap and human specimen (13 isolates)
in different hospitals tested in the preliminary screening.
Species NRRL n. a PVS-Fu n.b Diagnosis c Isolate source Date Origin
F. chlamydosporum - 4 FHB durum wheat 1994 Voghera
F. crookwellense - 6 FRR bread wheat 1989 Perugia
F. crookwellense - 406 FHB durum wheat 2008 Sassari
F. guttiforme 53131 864 Paronychia finger 2007 Milano
F. langsethiae d - 341 FHB wheat - -
F. pseudograminearum - 7 FRR durum wheat 1992 Foggia
F. solani 46443 93 Dermatomycosis foot 2004 Milano
F. solani 46440 97 Onychomycosis finger 2005 Milano
F. solani - 100 Onychomycosis toe 2006 Milano
F. solani 52832 95 Onychomycosis toe 2007 Milano
F. solani - 105 Onychomycosis toe 2010 Milano
F. solani 44937 107 - soil 2007 Sassari
F. solani 46672 108 - soil 2007 Cagliari
F. solani 44924 109 - soil 2007 Cagliari
F. solani 46492 110 - soil 2007 Nuoro
F. solani 46676 111 - soil 2007 Cagliari
F. subglutinans - 10 . soil 1998 Bari
F. subglutinans 22034 187 - maize - Iran
F. verticillioides - 400 - maize 2001 Bergamo
F. verticillioides 53119 112 Sepsis leukaemia-blood 2007 Ancona
F. verticillioides 53125 113 Sepsis kidney transplant-blood 2007 Novara
F. verticillioides 44894 88 Paronychia finger 2006 Milano
F. oxysporum - 222 - - - -
F. oxysporum 46489 123 - soil 2007 Nuoro
F. oxysporum 46480 124 - soil 2007 Nuoro
F. oxysporum 46603 89 Onycomycosis toe 2004 Milano
F. oxysporum 46595 126 Onycomycosis toe 2007 Milano
F. oxysporum 52682 127 Onycomycosis toe 2007 Milano
F. oxysporum 44899 128 Onycomycosis toe 2006 Milano
F. oxysporum - 516 - water tap 2013 Sassari
F. equiseti 46660 146 - soil 2007 Cagliari
F. equiseti 44916 147 - soil 2007 Cagliari
a NRRL Collection number of Agricultural Research Service (ARS).
b PVS-Fu n. Collection number of Dipartimento di Agraria, Sezione Patologia Vegetale ed Entomologia, Sassari, Italy.
c FRR Fusarium Foot Root Rot; FHB Fusarium Head Blight.
d Strains 01–113 kindly provided by Prof. Y. Mattila.
https://doi.org/10.1371/journal.pone.0221249.t001
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were prepared by growing the fungi on carboxymethyl cellulose (CMC) medium [31] for 7
days at 25˚C and 170 rpm in the dark. Cultures were filtered, the spores were collected by cen-
trifugation and the concentration was adjusted to ~ 106 colony–forming units (CFU)/ml in
sterile water. Ten microliters of the conidial suspension of each strain were plated on the
amended PDA. Three replicates were prepared for each inhibitor and concentration.
Measurement of Minimal inhibitory concentration (MIC)
The inhibitory activity of each compound was expressed as Minimal Inhibitory Concentration
(MIC) and represents the lowest concentration of active ingredient (μg/ml) that is sufficient to
inhibit fungal growth.
Measurement of Lethal Dose 50 (LD 50)
The Lethal Dose 50 of each compound was calculated as the concentration of active ingredient
(μg/ml) able to reduce by 50% the growth of the fungus in vitro.
Statistical analysis
Data on mycelium weight (mg of dry weight per Petri plate) and mycelium growth (mm per
Petri plate), obtained from separate experiments, were expressed as percentage of the relative
control treatment and pooled to perform statistical analyses. To compare the activities of dif-
ferent concentrations of each of the selected compounds, a one-way analysis of variance
(ANOVA) was performed, followed by multiple comparisons by Tukey HSD test at P = 0.01
using Minitab for Windows, release 17. Prior to performing the ANOVA, normality of
Table 2. List of 15 Fusarium spp. isolates of clinical relevance tested in the present study.
n. Species NRRL n. a PVS-Fu n.b Diagnosis Isolate source Date Origin Hospitalc
1 F. verticillioides - 604 Dead patient Hospital 2013 Nuoro NU
2 F. verticillioides 53129 86 Pneumonia Broncho alveolar lavage 2007 Varese V
3 F. verticillioides 46599 87 Onychomycosis Toe 2007 Milan M-1
4 F. verticillioides 53126 84 Chronic sinusitis Maxillary sinus pus 2007 Novara N
5 F. verticillioides 53122 83 Sepsis in leukemia Blood 2007 Milan M-3
6 F. verticillioides d 44894 88 Paronychia Finger 2006 Milan M
7 F. solani 53120 94 Sepsis Blood 2007 Milan M-3
8 F. solani 44903 96 Onychomycosis Toe 2006 Milan M-1
9 F. solani - 502 - Sink 2013 Sassari SS
10 F. solani 46443 93 Dermatomycosis Foot 2004 Milan M-1
11 F. oxysporum 46603 89 Onychomycosis Toe 2004 Milan M-1
12 F. oxysporum - 516 - Water tap 2013 Sassari SS
13 F. oxysporum 53121 92 Soft tissue Kaposi’s sarcoma Pus 2007 Milan M-2
14 F. oxysporum 46600 90 Dermatomycosis Foot 2007 Milan M-1
15 F. oxysporum 46606 91 Onychomycosis Toe 2005 Milan M-1
a NRRL n. Collection number of Agricultural Research Service (ARS).
b PVS-Fu n. Collection number of Dipartimento di Agraria, Sezione Patologia Vegetale ed Entomologia, Sassari, Italy.
c Locations of eight Italian hospitals sampled listed by city: A, Ancona (Marche region, central Italy); M-1, Sesto San Giovanni Hospital, Milan; M-2, hospital 2, Milan;
M-3, hospital 3, Milan; M-4, hospital 4, Milan; V, Varese (Lombardy region, northern Italy); N, Novara (Piedmont region, northern Italy); NU, Nuoro (Sardinia, Italy
island); T, Torino (Piedmont region, northern Italy); SS, Sassari (Sardinia, Italy island).
d Isolates in bold were included in the preliminary screening.
https://doi.org/10.1371/journal.pone.0221249.t002
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residuals was verified by the Shapiro-Wilk test, whereas assumption of homoscedasticity was
checked by the Levene test.
Results
Antifungal activity of magnolol 1 on a collection of representative isolates
of Fusarium spp.
The inhibitory effect of magnolol 1 on the dry weight of thirty-two Fusarium strains tested in
Vogel’s medium is reported on Table 3.
Table 3. Mycelium dry weight reduction of 32 Fusarium spp. isolates obtained from soil (10 isolates), diseased
plants or grain (9 isolates), a water tap and human specimen (13 isolates) in different hospitals treated with mag-
nolol at 0.5 mM.
Species PVS-Fu n.a Dry weight (% of control)
F. chlamydosporum 4 30.6 ± 11.4
F. crookwellense 6 56.5. ± 15.9
F. crookwellense 406 56.0 ± 10.0
F. guttiforme 864 0 ± 0
F. langsethiae 341 18.3 ± 2.4
F. pseudograminearum 7 28.5 ± 10.8
F. solani 93 43.6 ± 5.5
F. solani 97 0 ± 0
F. solani 100 66.6 ± 29.1
F. solani 95 64.9 ± 7.3
F. solani 105 49.0 ± 18.2
F. solani 107 43.3 ± 12.6
F. solani 108 34.3 ± 18.2
F. solani 109 0 ± 0
F. solani 110 25.7 ± 8.1
F. solani 111 34.3 ± 18.2
F. subglutinans 10 8.7 ± 2.1
F. subglutinans 187 4.1 ± 0.6
F. verticillioides 400 45.1 ± 22.3
F. verticillioides 112 8.4 ± 5.0
F. verticillioides 113 5.2 ± 2.0
F. verticillioides 88 43.1 ± 10.9
F. oxysporum 222 60.3 ± 23.9
F. oxysporum 123 42.9 ± 8.4
F. oxysporum 124 39.0 ± 3.9
F. oxysporum 89 22.3 ± 2.6
F. oxysporum 126 24.2 ± 3.6
F. oxysporum 127 80.0 ± 17.3
F. oxysporum 128 49.7 ± 14.7
F. oxysporum 516 67.1 ± 12.1
F. equiseti 146 21.5 ± 2.4
F. equiseti 147 0 ± 0
a PVS-Fu n. Collection number of Dipartimento di Agraria, Sezione Patologia Vegetale ed Entomologia, Sassari,
Italy.
https://doi.org/10.1371/journal.pone.0221249.t003
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Except for F. crookwellense 6, F. crookwellense 406, F. oxysporum 127, F. oxysporum 222, F.
oxysporum 516, F. solani 95, and F. solani 100, the remaining 25 Fusarium isolates underwent
a mycelium dry weight reduction greater than 50% when exposed to magnolol 1 at 0.5 mM
(Table 3).
Complete or almost complete inhibition was observed in eight isolates, four of them
belonging to clinical Fusarium collected from human specimen (PVS-Fu, 864; 95; 112; 113,
Table 2 and Table 3). Magnolol 1 at 0.5 mM was very effective on F. guttiforme 864 cultured
from a paronychial infection and against F. verticillioides 112 and F. verticillioides 113, col-
lected from pathological human blood, leading to complete inhibition of mycelium growth.
Complete inhibition was also observed for F. solani 97, whereas more than 50% reduction of
mycelium dry weight was obtained for F. solani 105 and F. solani 93. Similarly, onycomycosis-
causing F. oxysporum 89 and F. oxysporum 126 were inhibited by over 75%, whereas F. oxy-
sporum 127 was inhibited only by 20%.
Selection and activity of two conventional fungicides targeted at Fusarium
isolates of clinical relevance
Terbinafine and fluconazole, two conventional fungicides, were assayed over a range of 0.1–
10 μg/ml and 1–50 μg/ml, respectively, on a set of F. verticillioides, F. solani and F. oxysporum
isolates from human samples and clinical environment (Table 2). With different levels of
intensity, F. verticillioides isolates were the most sensitive, whereas F. solani isolates showed the
lowest sensitivity towards both fungicides (Fig A and Fig B in Supporting Information). In par-
ticular, F. verticillioides isolates were highly sensitive to terbinafine, with MICs ranging from 1
to 5 μg/ml and LD50 between 0.1 and 1 μg/ml (Table 4).
At 25 μg/ml, fluconazole was able to completely inhibit the vegetative growth of all F. verti-
cillioides isolates, whereas almost 60% mycelium growth inhibition was observed for F. solani
502 and for all F. oxysporum isolates. The mycelium growth of F. solani 94 and F. solani 96 was
not affected by fluconazole even at the highest concentration of 50 μg/ml. Even at lower con-
centrations (5–10 μg/ml), terbinafine showed more effective antifungal activity (growth
Table 4. LD50 and MIC values (in μg/ml) of terbinafine, fluconazole, magnolol 1 and honokiol 2 tested against Fusarium spp.
Terbinafine Fluconazole Magnolol 1 Honokiol 2
LD50 MIC LD50 MIC LD50 MIC LD50 MIC
F. verticillioides 604 0.1–0.5 1–5 10–25 10–25 10 - <50 >400 5–10 10–100
F. verticillioides 86 0.5–1 1–5 10–25 10–25 50 >400 5–10 10–100
F. verticillioides 87 0.5–1 1–5 10–25 10–25 5–10 >400 5 10–100
F. verticillioides 84 0.1–0.5 1–5 10–25 10–25 50–100 >400 5–10 5–10
F. verticillioides 83 0.1–0.5 1–5 10–25 10–25 10–50 >400 5–10 10–100
F. verticillioides 88 0.1–0.5 1–5 10–25 10–25 10–50 >400 5–10 10–100
F. solani 94 1–5 >10 >50 >50 100 >400 5–10 10–100
F. solani 96 1–5 >10 >50 >50 10–50 >400 5–10 10–100
F. solani 502 1–5 >10 >50 >50 5–10 >400 5–10 10–100
F. solani 93 1–5 >10 >50 >50 10–50 >400 5–10 5–10
F. oxysporum 89 1–5 5–10 >50 >50 5–10 >400 5–10 10–100
F. oxysporum 516 1–5 5–10 >50 >50 5–10 >400 5–10 10–100
F. oxysporum 92 1–5 1–5 >50 >50 5–10 >400 5–10 10–100
F. oxysporum 90 1–5 5–10 >50 >50 5–10 >400 5–10 10–100
F. oxysporum 91 1–5 5–10 >50 >50 5–10 >400 <5 10 -<100
https://doi.org/10.1371/journal.pone.0221249.t004
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inhibition being > 50%) than fluconazole in all isolates belonging to the three Fusarium spe-
cies complexes (Fig A and Fig B in Supporting Information).
Antifungal activity of magnolol 1, honokiol 2 and their derivatives 3–8
Isolates belonging to F. oxysporum were more sensitive to magnolol 1 compared to the other
species (Table 4). Magnolol 1 affected all isolates belonging to the three species complexes with
a mycelium growth inhibition >50% at 100 μg/ml; the trend was not significantly different at
200 μg/ml and for F. verticillioides 604, F. solani 502, F. oxysporum 89, F. oxysporum 90 and F.
oxysporum 91 even at 400 μg/ml (Fig C in Supporting Information). MIC of magnolol 1 was
>400 μg/ml for all the tested Fusarium isolates (Table 4).
Over a concentration range of 10–100 μg/ml, honokiol 2 completely inhibited mycelium
growth in all 15 fungal strains investigated (Fig D in Supporting Information). More than 50%
mycelium growth inhibition was observed in all Fusarium spp. when honokiol 2 was amended
at 10 μg/ml. In F. verticillioides 84, a fungus responsible for chronic sinusitis, honokiol 2
showed strong antifungal activity with MIC between 5 and 10 μg/ml (Table 4). Honokiol 2 was
more effective than magnolol 1 at inhibiting F. solani, with MIC ranging from 10 to 100 μg/ml,
except for F. solani 93, whose MIC was comprised between 5 and 10 μg/ml. Besides F. oxy-
sporum 91, antifungal activity of magnolol 1 was comparable to that of honokiol 2 in F. oxy-
sporum isolates, with a LD50 ranging from 5 to 10 μg/ml. However, magnolol 1 could not
completely inhibit fungal growth at the tested concentrations, whereas honokiol 1 did over a
range of 10–100 μg/ml.
A mono protection of the phenol-OH with an acetyl group in magnolol 1 (compound 3)
had a higher effect on MIC values in F. verticillioides 83, F. verticillioides 86, F. verticillioides 88
and F. solani 93 (Table 5 and Fig E in Supporting Information).
At 400 μg/ml, almost complete growth inhibition was observed in F. oxysporum 89, F. solani
93, F. verticillioides 83, F. verticillioides 84, F. verticillioides 86, and F. verticillioides 88. At
100 μg/ml, magnolol mono acetate 3 inhibited by 50% the mycelium growth of all the tested
strains (Fig E in Supporting Information). Conversely, magnolol mono glucopyranoside 8 was
not effective at concentration up to 400 μg/ml on all the Fusarium species complexes (Fig K in
Supporting Information).
Honokiol mono acetate 5 and 6 proved less effective than the parent compound, with LD50
and MIC values higher than those displayed by honokiol 2 (Table 5). At 100 μg/ml, except for
F. solani 94, F. solani 96 and F. solani 93, honokiol 2-mono acetate 5 and honokiol 4’-mono
acetate 6 inhibited by 50% the vegetative growth of all Fusarium isolates (Fig G and Fig H in
Supporting Information). The colony growth of F. verticillioides 87, F. verticillioides 88 and F.
oxysporum 90 was inhibited by 80% in the presence of honokiol 2-mono acetate 5 at 100 μg/
ml. Honokiol diacetate 7 was less effective against all the Fusarium species complexes (Table 5
and Fig I in Supporting Information). Complete protection of both phenol-OH groups in
magnolol 1 and honokiol 2 determined a reduction of their efficacy (Table 5 and Fig F and Fig
I in Supporting Information).
Compounds 1–7 showed comparable lipophilicity estimated by LogP between 4.99 and
5.03, while LogP 2.36 was calculated for magnolol mono glucopyranoside 8.
Comparison of antifungal activity of compounds 1–8 with the conventional
fungicides
When the activity of magnolol 1, honokiol 2 and their derivatives 3–8 was compared with that
of terbinafine and fluconazole, a different trend of efficacy was observed (Table 4 and Table 5
and Figs A-K in Supporting Information).
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With the exception of F. solani 94, LD50 of magnolol 1 for both F. solani and F. oxysporum
species complexes was lower than that of fluconazole. Magnolol 1 showed better or similar
inhibitory activity than fluconazole at 5 μg/ml, whereas honokiol 2 showed a higher inhibition
of mycelium growth compared to the conventional fungicide for all clinical Fusarium species
complexes (Figs B-D in Supporting Information). Conversely to terbinafine and fluconazole,
honokiol 2 showed comparable inhibitory activity against all three species complexes (Fig D in
Supporting Information). Table A in Supporting Information reports a comparison of μg/ml
and molarity for all investigated compounds with that of fluconazole and terbinafine. Further-
more, the growth inhibition data of terbinafine, fluconazole, magnolol 1 and honokiol 2 were
collected in four graphics where concentrations in μg/ml were converted to molarity (Fig 2A,
2B, 2C and 2D). In Fig 2A the summary effect of terbinafine, fluconazole, magnolol 1 and hon-
okiol 2 on F. oxysporum, F. solani and F. verticillioides is shown. Terbinafine and honokiol 2
were both able to inhibit mycelium growth effectively. Nevertheless, terbinafine, at the tested
clinical dosages, could not completely inhibit fungal growth as honokiol 2 did on all Fusarium
isolates over a range of 37.5–375 μM (10–100 μg/ml). The effect of magnolol 1 and fluconazole
is superimposable over a range of concentrations, roughly between 19 and 160 μM, though
magnolol 1 was more effective as vegetative growth inhibitor.
Comparable LD50 was observed on F. oxysporum 91 collected from onychomycosis, when
treated with terbinafine (1–5 μg/ml, 3.4–17 μM) and honokiol 2 (<5 μg/ml, < 18.8 μM)
(Table 4). At clinical dosages, fluconazole was not effective against this set of F. oxysporum iso-
lates (Fig 2B), whereas magnolol 1 and honokiol 2 were more effective, the latter being able to
provide complete fungal growth inhibition at 0.375 mM (100 μg/ml).
Except for F. solani isolates, terbinafine was able to inhibit mycelium growth over a range
between 3.4–34.3 μM (10–100 μg/ml), i.e., smaller by roughly one order of magnitude com-
pared to honokiol 2 (Fig 2C). Over a range of 5–10 μg/ml (18.8–37.5 μM), honokiol 2 was as
effective as terbinafine (10 μg/ml, 34 μM) in inhibiting the colony growth (MIC) of F. solani
93, isolated from foot dermatomycosis (Table 3). Moreover, at 10 μg/ml, honokiol 2 (37.5 μM)
had a similar effect compared to that of terbinafine (34 μM) in inhibiting F. solani 502 isolated













LD50 MIC LD50 MIC LD50 MIC LD50 MIC LD50 MIC LD50 MIC
F. verticillioides 604 10–50 >400 >400 >400 >400 >400 50–100 >100 >100 >100 >100 >100
F. verticillioides 86 10–50 200–400 >400 >400 >400 >400 50–100 >100 25–50 >100 >100 >100
F. verticillioides 87 10–50 >400 >400 >400 >400 >400 50–100 >100 25–50 >100 >100 >100
F. verticillioides 84 10–50 >400 >400 >400 >400 >400 50–100 >100 25–50 >100 >100 >100
F. verticillioides 83 10–50 200–400 >400 >400 >400 >400 25–50 >100 25–50 >100 >100 >100
F. verticillioides 88 10–50 100–400 >400 >400 >400 >400 25–50 >100 25–50 >100 >100 >100
F. solani 94 50–100 >400 >400 >400 >400 >400 >100 >100 >100 >100 >100 >100
F. solani 96 100–200 >400 >400 >400 >400 >400 >100 >100 >100 >100 >100 >100
F. solani 502 10–50 >400 >400 >400 >400 >400 50–100 >100 25–50 >100 >100 >100
F. solani 93 50–100 200–400 >400 >400 >400 >400 >100 >100 >100 >100 >100 >100
F. oxysporum 89 10–50 >400 >400 >400 >400 >400 25–50 >100 25–50 >100 >100 >100
F. oxysporum 516 10–50 >400 >400 >400 >400 >400 50–100 >100 25–50 >100 >100 >100
F. oxysporum 92 10–50 >400 >400 >400 >400 >400 25–50 >100 25–50 >100 >100 >100
F. oxysporum 90 10–50 >400 >400 >400 >400 >400 25–50 >100 25–50 >100 >100 >100
F. oxysporum 91 10–50 >400 >400 >400 >400 >400 25–50 >100 25–50 >100 >100 >100
https://doi.org/10.1371/journal.pone.0221249.t005
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from a hospital basin sink and, to a lesser extent, F. oxysporum 516 collected from a hospital
water tap (Table 4 and Fig A and Fig D in Supporting Information). Terbinafine and flucona-
zole were able to inhibit fungal growth of F. verticillioides with MIC value < 5 μg/ml
and< 25 μg/ml, respectively (Table 4), while honokiol 2 followed the same trend as terbina-
fine, providing a complete fungal growth inhibition at<100 μg/ml.
Discussion
The objective of this work was to propose ‘natural’ alternatives to the use of conventional fun-
gicides, even if this approach required the use of higher concentrations of the identified com-
pounds. The compounds we tested, namely magnolol 1 and honokiol 2, are commercially
available in large amounts and have been used in modern clinical practice in Eastern Asia,
while in the United States and Europe are considered cosmetic additives.
In a preliminary screening, the selection of Fusarium spp. from agricultural and human
sources provided a general information of the potential antifungal activity of magnolol 1
towards these fungi, including ubiquitous representatives of the F. solani and F. oxysporum
species complexes. With different ranges of intensity, magnolol 1 was able to control all F. oxy-
sporum and F. solani isolates sampled from human specimen. Magnolol 1 also proved a poten-
tial candidate to control F. subglutinans and, to a lesser extent, F. verticillioides 400, two species
able to infect corn. Data reported in Table 3 highlight a different sensitivity of isolates within
the same species complex, regardless of their origin.
Subsequently, this study was carried out on Fusarium spp. of clinical interest, aiming at test-
ing the antifungal activity of magnolol 1, honokiol 2 and their derivatives 3–8 as sustainable
alternatives to current clinical drug treatments, which suffer from frequent emergence of
Fig 2. The effect of different molarity solutions of terbinafine (red), fluconazole (yellow), magnolol 1 (blue), and honokiol 2 (green) on fungal
growth of: (A) Fusarium oxysporum, F. solani and F. verticillioides; (B) F. oxysporum; (C) F. solani and (D) F. verticillioides.
https://doi.org/10.1371/journal.pone.0221249.g002
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resistant pathogen populations. Two commercial fungicides with different mode of action, i.e.
terbinafine and fluconazole, were selected in order to compare their antifungal activity with
that of compounds 1–8 against all clinical Fusarium spp. isolates. Terbinafine, a tertiary allyla-
mine and one of the most effective antimycotic drugs used in human therapy, inhibits the
ergosterol biosynthesis by acting on the squalene epoxidation and is widely used for the treat-
ment of nail infections [32]. Fluconazole, an inhibitor of the lanosterol 14α-demethylase,
belongs to the azole SBI class I, whose activity is weaker than that of terbinafine. Although
acquired resistance against fluconazole was observed in Fusarium spp. of agricultural interest,
the fungicide is still being used in the clinical treatment of these fungi [33, 34]. Concentrations
of terbinafine and fluconazole were selected according to literature [30].
Magnolol 1, honokiol 2 and their derivatives 3–8 were tested at concentrations ranging
from twenty-five-fold lower and, roughly three-fold higher than those used to amend Vogel’s
medium in the preliminary assay. This concentration range allowed us to compare the species
diversity and the antifungal susceptibility profile of the clinical isolates with all tested. Over an
acceptable range of variability, percentage of growth inhibition of F. verticillioides 88, F. solani
93, F. oxysporum 89 and F. oxysporum 516 observed in Vogel’s assay with magnolol 1 was com-
parable to that observed on PDA, suggesting that growth inhibition is independent from the
cultural medium. In our screening, magnolol 1 and its structural isomer, honokiol 2, showed
effective antifungal activity. These compounds may prove useful in antimicrobial drug devel-
opment, based on their recognised multitarget bioactivities, market availability and almost safe
metabolic profile in human body [25, 26]. Moreover, the capacity of magnolol 1 and honokiol
2 to act on multiple cell targets can be the key to control infection by resistant fungi which do
not respond to conventional therapies.
When the concentrations applied were analysed in terms of molarity, a clearer comparison
of the antifungal activities of terbinafine, fluconazole, magnolol 1 and honokiol 2 was obtained.
Even though different ranges of molarity were taken into account, a very similar trend in the
activities of terbinafine and honokiol 2 was observed. In the case of F. oxysporum 91, honokiol 2
was very effective, thereby appearing as a promising antifungal agent in the treatment of ony-
chomycoses. Interestingly, the antifungal activity of honokiol 2 towards F. solani 93, isolated
from foot dermatomycosis, and, to a lesser extent, against F. solani 502, isolated from hospital
basin sink, was comparable to that exerted by terbinafine. Due to the acceptable metabolic pro-
file of honokiol 2 taken in oral dosage, these results suggest a potential application of this com-
pound in washing water contaminated by F. oxysporum and in the sanitation of sinks.
A pro-drug approach [29] was applied as a versatile strategy to improve the bioactivity of
these compounds by transformation of the hydroxyl groups of magnolol 1 and honokiol 2 in a
mono- and di-acetyl ester, respectively, and, in the case of magnolol 1, in a mono glucosyl ace-
tal 8. The antifungal activity of honokiol 2 dropped when one of the phenol-OH was protected
with an acetyl group (i.e. in compounds 5 and 6). The effect was less remarkable between hon-
okiol 4’-mono acetate 6 and honokiol 2-mono acetate 5, further highlighting the importance
of both phenol-OH groups in the activity of honokiol 2. On the contrary, magnolol mono ace-
tate 3 showed higher inhibitory activity than the corresponding parental compound, whereas
the bioactivity dropped when phenol-OH groups were protected with two acetyl groups.
Due to the presence of a glucosyl unit, magnolol mono glucopyranoside 8 was more hydro-
philic compared to compounds 1–7. Although a free phenol-OH group is present in the struc-
ture of this compound, it is possible that its poor antifungal activity is a result of its failure to
reach its target in the fungal cell through the lipophilic membrane.
Magnolol 1 and honokiol 2 are structural isomers, but the different position of one phenol-
OH group confers distinct conformations and electronic effects and, as a result, a different
reactivity (e.g., antioxidant activity) [7]. A C2-symmetry axis in magnolol 1 allows only one
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monoester isomer, whereas two distinct isomers can be produced after monoesterification of
honokiol 2. Phenol-OH groups in magnolol 1 have different acidity due to the formation of an
intramolecular H-bond between the two phenol-OH. On the contrary, in honokiol 2, the large
dihedral angle and the distance of the two phenol-OH groups reduce the conjugation effect.
These features reflect the different activity that monoesters and diesters of magnolol 1 and
honokiol 2 have displayed during in vitro assays. According to the position of the two phenol-
OH groups in the biphenyl structure, a different mechanism of action between magnolol 1 and
honokiol 2 might take place when these compounds interact with fungi.
Several modes of action of magnolol 1 and honokiol 2 were described towards fungi [35–
37]. Magnolol 1 interacts with ergosterol present in the cell membrane, inducing a partial dis-
ruption of the structure, but its mechanism of action is likely to differ from that of other inhib-
itors of sterol biosynthesis as it has proven effective also on fluconazole-resistant Candida spp.
isolates [38]. Cell wall components such as β-1,3-glucans were proposed as potential target of
magnolol, similarly to fungicides of the echinocandin family [39].
It is reasonable to hypothesize that other mechanisms underlay the antifungal activity of
magnolol 1 and honokiol 2 that may justify a differential action towards the three investigated
Fusarium species complexes. Recently, the role of honokiol 2 as activator of mitochondrial
ROS by mitochondrial dysfunction and depolarisation of mitochondrial membrane potential
in C. albicans was highlighted [40]. Moreover, honokiol 2 is able to hinder the high content of
pro-oxidant iron ions in fungi by sequestering the ion [41]. Having different targets and multi-
ple mechanisms of action, it is likely that honokiol 2 acts more effectively than magnolol 1 on
selected fungal targets. In fact, candidates that are able to induce dysfunction of mitochondrial
membrane and alteration of iron homeostasis represent thenew pharmacological leads cur-
rently under development [42]. The scarce toxicity of magnolol 1 upon dermal and oral
administration, which is even lower than that of honokiol 2 [25, 26], opens new straightfor-
ward clinical applications for this compound.
In conclusion, our findings suggest that magnolol 1, honokiol 2 and magnolol acetate 3
may represent promising alternatives for the treatment of fungal infections on both plants and
humans: they share a different mode of action compared to conventional antifungal drugs,
whose clinical application is jeopardized by the onset of resistance phenomena in fungal
populations. The low toxicity of magnolol 1 and honokiol 2, their low cost and their efficacy
against both yeast and filamentous fungi prompt further investigation on other fungal patho-
gens relevant in human or plant clinics and, to a large extent, on fungal pathogens of ecological
concern.
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Photos of mycelium growth of six Fusarium verticillioides isolates in the presence of magnolol
1 at 5 and 400 μg/ml in comparison with control (Fig M).
Photos of mycelium growth of four Fusarium solani isolates in the presence of magnolol 1 at 5
and 400 μg/ml in comparison with control (Fig N).
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